From biopharmaceuticals to financial services, Bay Area-based innovations are growing rapidly following last month’s ample venture capital investments. Having raised a collective $431 million, find out which local companies are growing their teams with their new cash.
Top San Francisco Tech Funding Rounds, October 2023
- MapLight
- Stampli
- Nirvana Insurance
- Nova Credit
- ScyllaDB
#5. $43 million, October 17
Eight Roads Ventures led the latest round of funding for ScyllaDB, a platform offering database solutions for high-throughput, low-latency workloads. The company pulled in $43 million to further its momentum and grow its team. This round brings ScyllaDB’s total venture funding to $103 million.
#4. $45 million, October 17
Originally built to help immigrants transition smoothly into a new country’s financial system, Nova Credit has since expanded from its flagship Credit Passport product to offer enterprises a cash flow underwriting product, Credit Atlas. The company raised Series C funding from lead investor Canapi Ventures to expand its product offering geographically.
#3. $57 million, October 17
Commercial insurance provider Nirvana is entering its next phase of growth after raising $57 million in Series B funding. Lightspeed, General Catalyst and others participated in the round. Nirvana is expanding its team with the influx of fresh capital, as well as enhancing its coverage and providing more products.
#2. $61 million, October 3
Stampli, a Bay Area-based developer of automated accounts payable solutions, pulled in Series D capital from lead investor Blackstone. The company helps more than 1,300 enterprise finance teams with tasks like invoice capture, expense allocation and more. With this latest raise, Stampli’s total funding surpasses $148 million.
#1. $225 million, October 30
MapLight, a biopharmaceutical company working to make targeted therapeutics for people with difficult-to-treat brain disorders, secured a large round of Series C funding from investors including Novo Holdings and 5AM Ventures. The company will put the capital toward continuing to develop treatments for neuropsychiatric and neurological conditions.
